ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company, has gained an increase of 4.58% in aftermarket trading session. As a result, ACAD stock is trading at $28.33 at the time of the writing. On Monday, ACAD closed the day at $27.09 after increasing by 5.16% during regular trading hours. The consistent increase could be attributed to plans of the company to resubmit NDA to the FDA.
Why ACAD on a Rise?
On Monday, ACAD announced that it plans to resubmit the supplemental New Drug Application (sNDA) to the pimavanserin for the treatment of hallucinations and delusions which are associated with dementia focused on Alzheimer’s disease psychosis (ADP). The resubmission of sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Q3 2021 Operational Results
In early November, ACAD released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September. The company generated total revenue of $131.6 million during the quarter against $120.5 million for the same period of 2020. The total operating expenses bore b the company during the quarter were $146.9 million against $206.4 million for the same period of 2020. The net loss suffered by the company during the three months was $14.4 million (or $0.09 per basic and diluted share) against $84.6 million (or $0.54 per basic and diluted share) for the same period of 2020.
Executive Commentary
Steve Davis, Chief Executive Officer of ACAD, while commenting on the results said that the company third-quarter results reflect the growth across all of the channels and the strong relative performance highlights the commercial team’s ability to drive the sales of NUPLAZID, the company’s prime product, in challenging environments. The company hopes that the upcoming times would provide it with further financial stability.
Future Outlook for ACAD
Statistics reveal that ACAD stock has mostly been following an increasing trajectory during the past few months. With analysts hoping the trend is expected to continue this way in future as well, potential investors should keep a close eye on the performance of ACAD stock.
